Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 16/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21625003 | 1.00 | MGLL (0.46) | MGLL | |
| SCHEMBL18446109 | 0.95 | MGLL (0.43) | MGLL | |
| SCHEMBL18418309 | 0.82 | MGLL (0.46) | MGLL | |
| SCHEMBL21625014 | 0.81 | MGLL (0.44) | MGLL | |
| SCHEMBL20396090 | 0.81 | MGLL (0.46) | MGLL | |
| SCHEMBL21636146 | 0.80 | MGLL (0.68) | MGLL | |
| SCHEMBL18422794 | 0.79 | MGLL (0.44) | MGLL | |
| SCHEMBL18423624 | 0.78 | MGLL (0.72) | MGLL | |
| SCHEMBL18446090 | 0.78 | MGLL (0.72) | MGLL | |
| SCHEMBL18423049 | 0.78 | MGLL (0.72) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309669-A1 | Heterocyclic Spiro Compounds As MAGL Inhibitors | PFIZER INC. (US) | 2021-10-07 | — | — | US | claimed |
| EP-3823723-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | Pfizer Inc. (US) | 2021-05-26 | — | — | EP | claimed |
| WO-2020016710-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER INC. (US) | 2020-01-23 | — | — | WO | claimed |
| US-20210309669-A1 | Heterocyclic Spiro Compounds As MAGL Inhibitors | PFIZER INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309669-A1 | Heterocyclic Spiro Compounds As MAGL Inhibitors | PFIZER INC. (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3823723-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | Pfizer Inc. (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3823723-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | Pfizer Inc. (US) | 2021-05-26 | — | — | EP | disclosed |
| CN-112469473-A | Heterocyclic spiro compounds as MAGL inhibitors | 辉瑞公司 | 2021-03-09 | — | — | CN | disclosed |
| US-10723711-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| WO-2020016710-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER INC. (US) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020016710-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER INC. (US) | 2020-01-23 | — | — | WO | disclosed |
| US-10428034-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3328849-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | Pfizer Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20180065943-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9845301-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2017-12-19 | — | — | US | disclosed |
| WO-2017021805-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20170029390-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029390-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | MAG, PYM1, HIF1AN | MGLL 22/4885 |
| US-20180065943-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | MAG, PYM1, HIF1AN | MGLL 22/4885 |
| US-20210309669-A1 | Heterocyclic Spiro Compounds As MAGL Inhibitors | MAG, ECH1, ECHS1 | MGLL 6/4885 |
| US-10723711-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | MAG, PYM1, HIF1AN | MGLL 22/4885 |
| US-10428034-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | MAG, PYM1, HIF1AN | MGLL 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.